

REMARKS

Claims 1-9 are pending in this divisional application and remain for consideration.

This Preliminary Amendment is being made in order to correct a transcription error in the claims. Through inadvertence, claim 1 recited the peptide of SEQ ID NO: 5, which was already the subject matter of another divisional application, Application Serial No. 10/632,889, filed July 31, 2003, instead of the peptide of SEQ ID NO: 7. This amendment is being made to correct this error.


The full sequence of the peptide of SEQ ID NO: 7 is recited in the specification at page 7, lines 15-19, along with the fact that the peptide is linear and has an acetylated amino terminus. Therefore, this amendment is fully supported by the specification and introduces no new matter.

Accordingly, entry of this Preliminary Amendment is therefore respectfully requested.

If any issues remain, the Examiner is respectfully requested to telephone the undersigned at (858) 450-0099 x302.

Respectfully submitted,

Date: February 2, 2005

  
Michael B. Farber, Ph.D., Esq.

CATALYST LAW GROUP, APC  
4220 La Jolla Village Drive, Suite 220  
San Diego, California 92122  
(858) 450-0099  
(858) 450-9834 (Fax)